Recent blog posts
NCT07538271 Anlotinib Dihydrochloride Extensive stage Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07538271 Anlotinib Dihydrochloride Extensive stage Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07538271 clinical trial report covering Anlotinib Dihydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07538258 Anlotinib Dihydrochloride Small cell lung cancer limited stage Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07538258 Anlotinib Dihydrochloride Small cell lung cancer limited stage Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07538258 clinical trial report covering Anlotinib Dihydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07538635 Axicabtagene Ciloleucel Large B-cell lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07538635 Axicabtagene Ciloleucel Large B-cell lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07538635 clinical trial report covering Axicabtagene Ciloleucel, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07539311 Rinatabart Sesutecan Gastrointestinal Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07539311 Rinatabart Sesutecan Gastrointestinal Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07539311 clinical trial report covering Rinatabart Sesutecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
ISRCTN15647953 [18F]Aldoview Hyperaldosteronism Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
ISRCTN15647953 [18F]Aldoview Hyperaldosteronism Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
ISRCTN15647953 clinical trial report covering [18F]Aldoview, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07539805 Sertraline Hydrochloride Depressive Disorder, Major Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07539805 Sertraline Hydrochloride Depressive Disorder, Major Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07539805 clinical trial report covering Sertraline Hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07538336 Emapalumab-LZSG Transplanted Lung Complication Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07538336 Emapalumab-LZSG Transplanted Lung Complication Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07538336 clinical trial report covering Emapalumab-LZSG, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07539753 Dalpiciclib Isethionate HR Positive/HER2 Negative/Node positive breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07539753 Dalpiciclib Isethionate HR Positive/HER2 Negative/Node positive breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07539753 clinical trial report covering Dalpiciclib Isethionate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20261524 Peturadol Migraine Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20261524 Peturadol Migraine Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
CTR20261524 clinical trial report covering Peturadol, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07539259 Spironolactone Aortic Valve Stenosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07539259 Spironolactone Aortic Valve Stenosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07539259 clinical trial report covering Spironolactone, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07541001 PRL3-zumab Locally Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07541001 PRL3-zumab Locally Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07541001 clinical trial report covering PRL3-zumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07542158 FLUORODOPA F-18 Parkinsonian Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07542158 FLUORODOPA F-18 Parkinsonian Disorders Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07542158 clinical trial report covering FLUORODOPA F-18, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →